Skip to main content
Equibles
YCBD logo

YCBD · cbdMD, Inc. · Metrics

Track YCBD — free

Use YCBD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research YCBD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.42 +0.03 (+7.22%) At close · Nov 6 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company’s ability to continue as a going concern is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that these financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$4.66M
Shares
11.21M
Volume · Nov 6 54.98K Avg daily vol (3M) 386.9K

YCBD metrics

77 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.42
Market cap
$4.66M

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
-4.7%
Price change (3M)
-31.4%
Price change (6M)
-55.4%
Price change (YTD)
-71.3%
Price change (1Y)
-52.6%
Trailing year
Price change (5Y)
—
52-week high
$2.27
52-week low
$0.35
Change from 52-week high
-82.9%
Change from 52-week low
+11.5%
Annualized volatility
149.3%
Annualized volatility (3M)
69.4%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.3
RSI (14D)
46.5
Price vs SMA 50
-9.8%
Price vs SMA 200
-40.8%
Avg volume (3M)
387,298
Relative volume
0.2
Average dollar volume
$178,108

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
11.21M

Valuation

12 metrics
P / E (TTM)
12.3
Trailing earnings · reciprocal yield 8.1%
PEG ratio
—
EV / revenue
0.1×
reciprocal yield 935.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 481.5%
P / book
0.5
reciprocal yield 188.9%
FCF yield
-55.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-66.4%

Historical valuation

8 metrics
P / E historical average (3Y)
5.0×
reciprocal yield 20.1%
P / E historical average (5Y)
5.0×
reciprocal yield 20.1%
EV / revenue historical average (3Y)
0.2×
reciprocal yield 491.8%
EV / revenue historical average (5Y)
0.3×
reciprocal yield 313.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
99.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
57.7%
Operating margin
-13.9%
Trailing 12 months
Net margin
-13.8%
Gross profit (TTM)
$12.07M
Operating profit (TTM)
−$2.90M
Net income (TTM)
−$2.89M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-11.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.81

Growth

11 metrics
Revenue growth YoY
+20.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$20.93M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+120.1%
Year over year · more shares
Revenue CAGR (3Y)
-18.5%
Revenue CAGR (5Y)
-14.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-35.2%
Return on assets
-22.0%
Debt / equity
0.0
Current ratio
2.5
EBITDA (TTM)
−$69.23M
Free cash flow (TTM)
−$2.41M
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.11M
Latest balance sheet
Cash & equivalents
$2.12M
Total assets
$13.15M
Total debt
$7,321

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.22M
Capital expenditures (TTM)
$191,419
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$1.64M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
27
13F filer change QoQ
+2
Institutional ownership
8.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
5.0%
Private-fund adviser ownership
2.5%
Active holders' share change QoQ
-12.7%
Holder tenure
3.4
Price vs estimated holder cost
-26.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.1%

Short interest

3 metrics
Short interest
4.9%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1644903 CUSIP 12482W408 13F (30d) 9 filings 7 filers Visit website Investor relations